Compare NTB & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTB | NUVB |
|---|---|---|
| Founded | 1858 | 2018 |
| Country | Bermuda | United States |
| Employees | 1306 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | 2016 | N/A |
| Metric | NTB | NUVB |
|---|---|---|
| Price | $49.08 | $8.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $50.67 | $9.63 |
| AVG Volume (30 Days) | 148.4K | ★ 10.2M |
| Earning Date | 10-28-2025 | 11-03-2025 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | ★ 17.07 | N/A |
| EPS | ★ 5.27 | N/A |
| Revenue | ★ $599,452,000.00 | $26,748,000.00 |
| Revenue This Year | $4.46 | $283.17 |
| Revenue Next Year | N/A | $340.98 |
| P/E Ratio | $9.32 | ★ N/A |
| Revenue Growth | 4.60 | ★ 1137.19 |
| 52 Week Low | $34.77 | $1.54 |
| 52 Week High | $49.22 | $8.70 |
| Indicator | NTB | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 75.85 | 76.08 |
| Support Level | $44.36 | $7.46 |
| Resistance Level | $46.76 | $8.24 |
| Average True Range (ATR) | 0.81 | 0.62 |
| MACD | 0.24 | 0.13 |
| Stochastic Oscillator | 95.99 | 97.20 |
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It operates the business through three geographic segments, Bermuda, Cayman Islands, the Channel Islands and the UK. The company offers banking services, comprised of retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. The company generates a majority of its revenue from Bermuda, and the Cayman Islands segments.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.